AVI BioPharma, Inc. Awarded $28 Million Biodefense Research Contract By Department of Defense/DTRA
12/4/2006 10:44:43 AM
PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq: AVII), has executed a two-year $28 million research contract with the Defense Threat Reduction Agency (DTRA) of Fort Belvoir, Va., an agency of the United States Department of Defense (DoD). The contract will fund AVI’s development of antisense therapeutics to treat the effects of Ebola, Marburg and Junin hemorrhagic viruses, which are seen as biological warfare and bioterrorism agents.
>>> Discuss This Story
comments powered by